- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03113994
Statin Monotherapy for Treatment of Endocrine Metabolic Disease Risk (RoBaCO)
The Efficacy and Safety of Rosuvastatin for Modifying Bone Mass and Cardiometabolic Disease Outcomes
Rationale: After having a spinal cord injury (SCI), people develop changes in their body composition that influences their long-term health. Individuals with paralysis after SCI will have large declines in their bone density ant increases in fat mass which increases their risk of fracture and heart disease. Therapies to prevent SCI-related changes in body composition and their health effects are needed. Drugs known as "statins" used often to reduce high cholesterol, may help to reduce bone loss and inflammation.
Hypothesis: Among adults with SCI for a long time, treatment with a drug named Rosuvastatin or a sugar pill, with supplements (coenzyme Q10, calcium and vitamin D), for twelve months can decrease their endocrine metabolic disease risk by increasing bone density and reducing inflammation.
Study Design: A clinical trial will be conducted in Toronto, Ontario and Miami, Florida. Subjects will get statin therapy or placebo (sugar pill) by chance. Study subjects and research staff will not know whether they are taking the study drug or a sugar pill until after the study
Subjects: Fifty-four adults (age 18-60 years) with a long-term SCI and no movement below their level of injury.
Treatment: Subjects will be prescribed Rosuvastatin 10 mg daily or a sugar pill. In addition, all subjects will receive 100 mg of Co-Q10 daily, calcium carbonate 1250 mg and, vitamin D 2,000 IU once a day.
Data Collected: Subjects' bone density will be collected at the start and end of the study. Change in bone density between the two groups will be compared to see if one is better. Blood samples will be collected quarterly to make sure subjects are safe and do not develop problems with their liver or muscles and to measure the effects of the study drugs on inflammation throughout the body.
Clinical Implications: Statins may be safe and effective therapy for adults living with SCI who are at increased risk of endocrine metabolic disease as they age.
Study Overview
Status
Conditions
Detailed Description
Rationale: Individuals with motor-complete spinal cord injury (SCI) undergo dramatic changes in body composition in the first 18 months post-injury, including declines in bone mineral density (BMD) that increase lower-extremity fragility fracture risk, and increases in fat mass that increase cardio-metabolic disease (CMD) risk. While statins are an effective treatment for dyslipidemia, research evidence suggests additional pleiotropic effects on bone through promotion of osteogenesis, suppression of osteoblast apoptosis, and inhibition of osteoclastogenesis. There are currently no effective therapies to treat sublesional osteoporosis (SLOP) and reduce the risk of fragility fractures in individuals with SCI.
Hypothesis: Twelve months of statin therapy with concurrent coenzyme Q10 (CoQ10), to reduce risk of statin neuromyotoxicity, and standard care (calcium 1250mg OD and vitamin D3 2000IU OD) will be superior to placebo with CoQ10 and standard care, for augmenting knee region BMD and reducing inflammatory stress (hs-CRP), thereby reducing endocrine metabolic disease risk.
Objective: To determine the safety and efficacy of statin therapy for augmenting distal femoral BMD among adults with chronic motor-complete SCI in Toronto, Ontario and Miami, Florida.
Study Design: Multi-centre, double-blind, randomized controlled Phase II safety and efficacy trial.
Subjects: Consenting men and premenopausal women (N=54, age 18-60 yrs) with chronic (≥2 years) spinal cord injury with a neurological level between C1-T10 and an AIS category of A/B.
Intervention: Rosuvastatin 10 mg po daily at night versus placebo for 12 months. All subjects will receive osteoporosis standard care (calcium carbonate 1250mg po daily and vitamin D3 2000 IU po daily) to maintain bone mass and CoQ10 100mg po daily to prevent statin-induced myopathy.
Outcomes: Primary safety outcomes: i) establish the safety of rosuvastatin in chronic SCI by reporting the frequency of myotoxicity and type II diabetes onset; ii) frequency and mean duration of liver transaminase elevations in the rosuvastatin and placebo groups. Primary efficacy outcome: measure the mean between group absolute changes in distal femur areal BMD (aBMD, g/cm2) from baseline to one year. Secondary efficacy outcomes: will examine the mean absolute changes from baseline in: i) volumetric BMD (vBMD, g/cm3); ii) markers of bone turnover - Bone Specific Alkaline Phosphatase (BALP), telopeptide (CTX), Sclerostin and RANK Ligand (RANK-L); iii) serum inflammatory markers including high sensitivity C-reactive Protein (hs-CRP), Interleukin-1ß (IL-1ß). interleukin-6 (IL-6), tumor necrosis factor - alpha (TNF-alpha), erythrocyte sedimentation rate (ESR); and, iv) lipid profile; low density lipoprotein cholesterol (LDL), high density lipoprotein cholesterol (HDL), triglycerides, and total cholesterol Clinical Implications: Should rosuvastatin prove to be safe and efficacious for reducing endocrine metabolic disease risk for adults with chronic SCI, the results will advance the health of people with SCI by reducing the frequency and severity of heart disease and fracture as they age, with a single intervention.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M4G 3V9
- University Health Network - Toronto Rehab Lyndhurst Centre
-
-
-
-
Florida
-
Miami, Florida, United States, 33136
- University of Miami Miller School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult (age 18-60 years)
- Motor complete SCI (C1-T10 AIS A/B)
- 2 years post-injury
- Have a telephone, and ability to attend the study visits
- Able to take oral medications and swallow independently
- Can provide free and informed consent
- Ability to understand instructions in English
- May report current use of oral alendronate 10mg daily or 70mg weekly or risedronate 5mg daily, 30mg weekly or 150mg monthly
Exclusion Criteria:
These criteria are intended to exclude those in whom; Rosuvastatin would be unsafe, DXA/pQCT measurement or biomarker assessment would be invalid, or in whom other co-morbid health conditions may confound the study results. Exclusion criteria include:
- Current and/or one year prior to enrolment treatment with any statin such as atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, simvastatin and rosuvastatin.
- Current treatment with IV bisphosphonate, denosumab, recombinant PTH, ovarian hormone therapy, an oral contraceptive, Immunosuppressants (Including Cyclosporine) and fusidic acid.
- Known allergy to Rosuvastatin, lactose powder, CoQ10, calcium carbonate, vitamin D2 and vitamin D3, or any other ingredient found in rosuvastatin, placebo or study supplements.
- History of Paget's disease, osteomalacia, steroid induced osteoporosis, or untreated parathyroid or untreated thyroid disease.
- Subjects with history of stage 4 chronic kidney disease. (124)
- Current Weight ≥136 kg.
- Bilateral knee region metal implants (hardware), history of bilateral knee region contracture >30 degrees, fracture or any other bilateral knee region pathology which would preclude accurate DXA assessment of one limb.
- Post-menopausal women (absence of menses for a minimum of 1 year).
- Women with amenorrhea due to bilateral surgical removal of the ovaries and/or uterus (women with amenorrhea due to spinal cord injury are able to participate).
- Pregnancy or lactation.
- Female of child-bearing potential who is engaged in active heterosexual relations and is not using appropriate birth control methods. Appropriate methods of birth control will include: surgical sterilization at least 6 months prior to using study drug or sexual activity restricted to a vasectomized partner, barrier contraception with a condom or diaphragm in conjunction with spermicidal gel in use at least 30 days prior to using study drug OR sexual abstinence as a lifestyle.
- History of liver disease or abnormal Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT), ≥1.5 times the upper limit of the normal reference range at enrolment.
- History of symptomatic hypocalcemia or hypophosphatemia.
- Concurrent treatment with prednisone (>7.5mg/day for 90 days).
- Vitamin D deficiency (Serum Vitamin D level <75nmol/L) after completing 8 to 12 weeks of treatment for Vitamin D deficiency as per the Vitamin D correction protocol (Appendix Page 1).
- History of heart attack or stroke.
- Untreated hypertension defined as: elevated BP above (135/85mmHg) assessed with an automated blood pressure cuff at 3 distinct time points in a 7-10 day period.(125, 126)
- Current alcohol or street drug abuse.
- Any illness or condition interfering with the trial conduct or subject safety.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
100mg CoQ10, daily for 12 months
1250mg Calcium Carbonate, daily for 12 months
2000IU Vitamin D, daily for 12 months
Placebo, daily for 12 months
|
Active Comparator: Rosuvastatin
|
10mg Rosuvastatin, daily for 12 months
100mg CoQ10, daily for 12 months
1250mg Calcium Carbonate, daily for 12 months
2000IU Vitamin D, daily for 12 months
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline in areal BMD of the knee region
Time Frame: Baseline and 12 months (or study completion)
|
Dual Xray Absorptiometry (DXA) Assessment of areal bone mineral density (aBMD) of the knee region
|
Baseline and 12 months (or study completion)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline in Low density lipoprotein cholesterol (LDL)
Time Frame: Baseline and 12 months (or study completion)
|
Serum assessment of LDL
|
Baseline and 12 months (or study completion)
|
Change from Baseline in high density lipoprotein cholesterol (HDL)
Time Frame: Baseline and 12 months (or study completion)
|
Serum assessment of HDL
|
Baseline and 12 months (or study completion)
|
Change from Baseline in triglycerides (TG)
Time Frame: Baseline and 12 months (or study completion)
|
Serum assessment of TG
|
Baseline and 12 months (or study completion)
|
Change from Baseline in total cholesterol
Time Frame: Baseline and 12 months (or study completion)
|
Serum assessment of cholesterol
|
Baseline and 12 months (or study completion)
|
Change from Baseline in High sensitivity C-reactive Protein (hsCRP)
Time Frame: Baseline and 12 months (or study completion)
|
Serum assessment of hsCRP
|
Baseline and 12 months (or study completion)
|
Change from Baseline in Interleukin-1ß (IL-1ß)
Time Frame: Baseline and 12 months (or study completion)
|
Serum assessment of IL-1ß
|
Baseline and 12 months (or study completion)
|
Change from Baseline in interleukin-6 (IL-6)
Time Frame: Baseline and 12 months (or study completion)
|
Serum assessment of IL-6
|
Baseline and 12 months (or study completion)
|
Change from Baseline in tumor necrosis factor - alpha (TNF-alpha)
Time Frame: Baseline and 12 months (or study completion)
|
Serum assessment of TNF-alpha
|
Baseline and 12 months (or study completion)
|
Change from Baseline in erythrocyte sedimentation rate (ESR)
Time Frame: Baseline and 12 months (or study completion)
|
Serum assessment of ESR
|
Baseline and 12 months (or study completion)
|
Change from Baseline in Bone Specific Alkaline Phosphatase (BALP)
Time Frame: Baseline, 6 months and 12 months (or study completion)
|
Serum assessment of BALP
|
Baseline, 6 months and 12 months (or study completion)
|
Change from Baseline in C-telopeptide (CTX)
Time Frame: Baseline, 6 months and 12 months (or study completion)
|
Serum assessment of CTX
|
Baseline, 6 months and 12 months (or study completion)
|
Change from Baseline in Sclerostin
Time Frame: Baseline, 6 months and 12 months (or study completion)
|
Serum assessment of Sclerostin
|
Baseline, 6 months and 12 months (or study completion)
|
Change from Baseline in RANK Ligand (RANK-L)
Time Frame: Baseline, 6 months and 12 months (or study completion)
|
Serum assessment of RANK-L
|
Baseline, 6 months and 12 months (or study completion)
|
Change from Baseline in volumetric BMD of the tibia (pQCT)
Time Frame: Baseline and 12 months (or study completion)
|
Peripheral Quantitative Computed Tomography (pQCT) assessment - Toronto Site Only
|
Baseline and 12 months (or study completion)
|
Change from Baseline in volumetric BMD of the tibia (HR-pQCT)
Time Frame: Baseline and 12 months (or study completion)
|
High Resolution Peripheral Quantitative Computed Tomography (HR-pQCT) assessment - Toronto Site Only
|
Baseline and 12 months (or study completion)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in visceral adipose tissue
Time Frame: Baseline and 12 months (or study completion)
|
Whole Body DXA assessment of body composition
|
Baseline and 12 months (or study completion)
|
Changes in lean mass
Time Frame: Baseline and 12 months (or study completion)
|
Whole Body DXA assessment of body composition
|
Baseline and 12 months (or study completion)
|
Changes in aortic arterial stiffness
Time Frame: Baseline and 12 months (or study completion)
|
Assessment of Aortic Pulse Wave Velocity (aPWV)
|
Baseline and 12 months (or study completion)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: B. Catharine Craven, BA, MD, FRCPC, MSc, Toronto Rehabilitation Institute - UHN
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Wounds and Injuries
- Musculoskeletal Diseases
- Trauma, Nervous System
- Spinal Cord Diseases
- Insulin Resistance
- Hyperinsulinism
- Bone Diseases
- Bone Diseases, Metabolic
- Metabolic Syndrome
- Osteoporosis
- Spinal Cord Injuries
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites
- Gastrointestinal Agents
- Micronutrients
- Anticholesteremic Agents
- Hypolipidemic Agents
- Lipid Regulating Agents
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Vitamins
- Bone Density Conservation Agents
- Calcium-Regulating Hormones and Agents
- Antacids
- Vitamin D
- Rosuvastatin Calcium
- Calcium
- Calcium, Dietary
- Calcium Carbonate
- Coenzyme Q10
- Ubiquinone
Other Study ID Numbers
- 2016-350642
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metabolic Syndrome
-
Universidad de los Andes, ChileCompleted
-
SanofiBristol-Myers SquibbCompletedMetabolic Syndrome xUnited States
-
Taipei Medical University WanFang HospitalUnknownMetabolic Cardiovascular SyndromeTaiwan
-
Mayo ClinicCompleted
-
The Catholic University of KoreaCompletedMetabolic Syndrome X | Metabolic Cardiovascular Syndrome | Insulin Resistance Syndrome X | Dysmetabolic Syndrome XKorea, Republic of
-
University of HohenheimGerman Federal Ministry of Education and ResearchCompleted
-
Charite University, Berlin, GermanyRecruitingMetabolic Syndrome, Protection AgainstGermany
-
Wageningen University and ResearchPhilips Healthcare; TNO; Friesland Campina; Albert Heijn; Menzis; Smart with food; Vi... and other collaboratorsCompletedMetabolic Syndrome, Protection AgainstNetherlands
-
Cairo UniversityCompletedMetabolic Syndrome in WomenEgypt
-
Andalas UniversityHasanuddin University; Universitas Sumatera UtaraCompletedMetabolic Syndrome, Protection AgainstIndonesia
Clinical Trials on Rosuvastatin Calcium
-
AstraZenecaCompletedDyslipidemia | HypercholesterolemiaUnited States
-
AstraZenecaCompleted
-
Shanghai Zhongshan HospitalUnknownNon-ST-elevation Acute Coronary SyndromesChina
-
Seung-Jung ParkCardioVascular Research Foundation, KoreaCompleted
-
Nanjing First Hospital, Nanjing Medical UniversityUnknownAcute Coronary SyndromeChina
-
University of Roma La SapienzaUnknown
-
Cross Research S.A.Zambon SpACompleted
-
Ottawa Hospital Research InstituteUnknownVenous ThromboembolismCanada, Norway
-
AstraZenecaCompletedFamilial HypercholesterolaemiaUnited States, Netherlands, Norway, Canada, Belgium
-
EMSRecruitingDyslipidemia Associated With Type II Diabetes MellitusBrazil